Search Results
Aug 06, 2026, 08:05 ET IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.
More news about: IceCure Medical
Aug 06, 2026, 08:00 ET Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
1 trials for HWK-007 and HWK-016. HWK‑007 is being evaluated in patients with non-squamous, EGFR wild-type non-small cell lung cancer; platinum-resistant ovarian cancer; and endometrial cancer (NCT07444814). The study design was presented as a Trials-in-Progress poster at the
More news about: Whitehawk Therapeutics, Inc.
Aug 06, 2026, 07:30 ET Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
event.About ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed
More news about: Nuvation Bio, Inc.
Aug 06, 2026, 07:00 ET Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease.Patients are encouraged
More news about: Insmed Incorporated
Aug 06, 2026, 00:51 ET Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength
first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), HANSIZHUANG has been approved for marketing in over 40 countries and regions. HLX43 has shown significant advantages, with a favorable efficacy and safety profile in non-small cell lung cancer (NSCLC), gynecological tumors, and other
More news about: Fosun
Aug 05, 2026, 20:00 ET Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
IO-naïve melanoma (acral and mucosal subtypes). A global, multi-center, Phase 3 clinical study (NCT06797297) in IO-resistant squamous non-small cell lung cancer (NSCLC) has also been initiated. As part of a license and collaboration agreement, Innovent and Takeda are co-developing IBI363/TAK-928 globally
More news about: Innovent Biologics
Aug 05, 2026, 16:02 ET GRAIL Reports Second Quarter 2026 Financial Results
compared with USPSTF A & B recommended screenings (breast, cervical, colorectal, and lung) and a 3x increase in number of cancers detected as compared with USPSTF A, B & C ratings (breast, cervical, colorectal, lung and prostate).53% of newly detected cancers were identified in Stage I and
More news about: GRAIL, Inc.
Aug 05, 2026, 11:01 ET Cold Spring Harbor Laboratory and Northwell Health lead international cohort of researchers to develop more than 150 next-generation cancer treatment models
developed organoids representing a wide range of malignancies, including pancreatic, breast, endometrial, colorectal, bladder, ovarian, head and neck, and lung cancers.
More news about: Cold Spring Harbor Laboratory
Aug 05, 2026, 08:30 ET IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.
More news about: IceCure Medical
Aug 05, 2026, 08:17 ET Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
reported data from a blinded validation cohort of 81 subjects (colorectal and lung cancer patients = 59, healthy controls = 22) and are extremely encouraged by the results; the early-stage cancer detection of 95% of stage I and II
More news about: VolitionRx Limited
Aug 05, 2026, 08:00 ET SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer
in heavily pre-treated patients with small cell lung cancer and other neuroendocrine carcinomas, supporting advancement of the program into late-stage development.About the BrenDeLL-Lung01 Phase 3 Clinical TrialBrenDeLL-Lung01 (
More news about: SystImmune, Inc.
Aug 05, 2026, 06:45 ET Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer (
More news about: Eli Lilly and Company
Aug 05, 2026, 05:01 ET American Lung Association Launches New Initiative in the Bronx to Help Residents with Lung Disease Amid Rising Air Pollution
Lung.org.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Aug 04, 2026, 16:05 ET TransMedics Reports Second Quarter 2026 Financial Results
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2026.
More news about: TransMedics Group, Inc.
Aug 04, 2026, 16:01 ET Rigel Reports Second Quarter 2026 Financial Results
that over 229,000 adults in the U.S. will be diagnosed with lung cancer in 2026. Lung cancer is the leading cause of cancer death in the U.S., with non-small cell lung cancer (NSCLC) being the most common type accounting for 77% of all lung cancer diagnoses.2 RET fusions are implicated in
More news about: Rigel Pharmaceuticals, Inc.
Aug 04, 2026, 16:01 ET AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
BiTE molecule.In May, the European Commission approved IMDYLLTRA as a monotherapy for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) who require systemic therapy following disease progression on or after first-line platinum-based chemotherapy.Also in May,
More news about: Amgen
Aug 04, 2026, 14:42 ET Brayton Purcell LLP announces $47 Million Verdict in the Fourth Artificial Stone Countertop Fabrication Silicosis Trial
specialist), Dr. Michael Ellenbecker, CIH (certified industrial hygienist), Dr. Mark Nicas, CIH (certified industrial hygienist), Dr. David Ross, M.D. (lung transplants), Dr. Andrew McClintock Greenberg, M.D. (pulmonologist), Dr. Richard Cohen (occupational medicine and epidemiology) and James Mills (forensic
More news about: Brayton Purcell LLP
Aug 04, 2026, 13:23 ET 37 Kaiser Permanente hospitals recognized by U.S. News & World Report
earned high-performing ratings in dozens of areas of care, including:Cancer care and treatment, such as colon cancer surgery and lung cancer surgery (26 hospitals)Cardiac care and treatment, such as heart failure treatment and heart bypass surgery (33 hospitals)Musculoskeletal
More news about: Kaiser Permanente
Aug 04, 2026, 12:05 ET Tampa General Is the Top-Ranked Hospital in the Tampa Bay Region for the 11th Year in a Row, According to U.S. News & World Report
Pulmonology & Lung Surgery – ranked #49 nationally, marking the first year the specialty has ranked among the nation's top 50 hospitals
More news about: Tampa General Hospital
Aug 04, 2026, 10:37 ET New Partnership Brings Medically Tailored Meals and Grocery Boxes to Eligible Medicaid Members in Oswego County
planYou have a chronic or high-risk conditionCommon qualifying conditions include:Diabetes, heart disease, stroke, lung disease, HIV, cancerPregnancy-related nutrition-sensitive, mental or behavioral health conditionsHow to Check Eligibility
More news about: Umoja Health
Aug 04, 2026, 09:48 ET Ochsner ranked No.1 in Louisiana by U.S. News & World Report
lung surgery have been ranked among the Top 50 in the nation.
More news about: Ochsner Health
Aug 04, 2026, 08:00 ET Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
ESMO.About ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed
More news about: Nuvation Bio Inc.
Aug 04, 2026, 06:52 ET Behind Every Breath Is a Story: World NTM Day 2026 Spotlights the Patients Behind an Underrecognized Lung Disease
impact of NTM lung disease.NTM lung disease is different from tuberculosis and is generally not considered contagious from person to person. The bacteria are common in the environment, but most people who are exposed do not become ill. Risk is higher among people with underlying lung conditions such
More news about: NTM Info & Research (NTMir)
Aug 04, 2026, 06:52 ET Detrás de cada respiro hay una historia: El Día Mundial de las NTM 2026 pone en primer plano una enfermedad pulmonar poco reconocida
https://www.multivu.com/ntm-info-and-research/9410751-es-world-ntm-day-2026-spotlights-lung-disease La enfermedad pulmonar por micobacterias no tuberculosas, o NTM, es causada por bacterias que
More news about: NTM Info & Research (NTMir)
Aug 04, 2026, 06:00 ET IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
trial (neoadjuvant primary UM) to be presented at ESMOUpdated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) in small-cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC) patients to be presented at ESMO Announced clinical collaboration with Roche to evaluate
More news about: IDEAYA Biosciences, Inc.